Not Yet Recruiting
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
NCT06501664
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
- Locations
-
Not specified